What do systematic reviews say?

Infliximab vs placebo

Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  RR 1.39 [1.21, 1.6]
  1 study · 728 participants
  High

Infliximab vs placebo

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 529 participants
  High

Infliximab vs placebo

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Low

Infliximab vs placebo

Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  RR 1.51 [1.23, 1.85]
  1 study · 728 participants
  Moderate

Infliximab vs placebo

Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  RR 1.44 [1.16, 1.79]
  1 study · 728 participants
  Moderate

Adalimumab vs placebo

Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  RR 1.23 [1.06, 1.43]
  2 studies · 767 participants
  Moderate

Adalimumab vs placebo

Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).

• The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
  RR 1.73 [1.28, 2.34]
  2 studies · 767 participants
  Moderate

Etrolizumab vs placebo

Etrolizumab probably leads to lower failure to enter clinical remission at week 10 compared with placebo (moderate certainty).

• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.86 [0.77, 0.95]
  1 study · 119 participants
  Moderate
• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.81 [0.68, 0.96]
  1 study · 59 participants
  Moderate

Etrolizumab vs placebo

Etrolizumab showed no clear difference in failure to respond at week 10 compared with placebo (moderate certainty).

• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.75, 1.23]
  1 study · 119 participants
  Moderate

Etrolizumab vs placebo

Etrolizumab showed no clear difference in failure to enter endoscopic remission at week 6 compared with placebo (moderate certainty).

• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.98 [0.9, 1.06]
  1 study · 119 participants
  Moderate
• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.92 [0.85, 1]
  1 study · 119 participants
  Moderate

Etrolizumab vs placebo

Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).

• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.75 [0.57, 0.99]
  1 study · 124 participants
  Moderate

Etrolizumab vs placebo

Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).

• Etrolizumab for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.92 [0.36, 2.34]
  2 studies · 165 participants
  Low

Methotrexate vs placebo

Methotrexate showed no clear difference in remission and complete withdrawal from steroids compared with placebo (low certainty).

• Methotrexate for induction of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.96 [0.58, 1.59]
  1 study · 67 participants
  Low

Methotrexate vs 6‐mercaptopurine

It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 6‐mercaptopurine (very low certainty).

• Methotrexate for induction of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.74 [0.43, 1.29]
  1 study · 26 participants
  Very low

Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).

• Methotrexate for induction of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 2.33 [0.66, 3.64]
  1 study · 20 participants
  Very low

Vedolizumab vs placebo

Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.86 [0.8, 0.91]
  4 studies · 606 participants
  High

Vedolizumab vs placebo

Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.68 [0.59, 0.78]
  3 studies · 601 participants
  Moderate

Vedolizumab vs placebo

Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.82 [0.75, 0.91]
  3 studies · 583 participants
  High

Vedolizumab vs placebo

Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.67 [0.59, 0.77]
  1 study · 373 participants
  Moderate

Vedolizumab vs placebo

Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).

• Vedolizumab for induction and maintenance of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
  RR 0.58 [0.49, 0.68]
  1 study · 373 participants
  Moderate